Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

NIH 3OTHER 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5Leukemia, Myeloid, Chronic-Phase 2Leukemia, Myeloid, Acute 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Myeloid 1Leukemia 1Hematologic Tumors 1Hematologic Neoplasms 1Blast Crisis 1

Interventions

Imatinib Mesylate 15Dasatinib 14nilotinib 8olverembatinib 4asciminib 4ponatinib 3Cyclosporine 3bosutinib 2Methotrexate 2Homoharringtonine 2Cyclophosphamide 24-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide 2inecalcitol 1flumatinib 1fludarabine phosphate 1elsulfavirine 1Whole-Body Irradiation 1Transplantation 1Radiotherapy 1Peripheral Blood Stem Cell Transplantation 1PF-114 1Mycophenolic Acid 1Interferon-alpha 1Hydroxyurea 1Fentanyl 1Everolimus 1Cytarabine 1Cord Blood Stem Cell Transplantation 1Busulfan 1BMS-833923 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Leukemia, Myeloid, Chronic-Phase × Homoharringtonine × Clear all
NCT04126681 2025-03-03

A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase

Ascentage Pharma Group Inc.

Phase 2 Completed
144 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT00114959 2015-01-15

Homoharringtonine With Oral Gleevec in Chronic, Accelerated and Blast Phase Chronic Myeloid Leukemia (CML)

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 2 Terminated
15 enrolled 6 charts
MyeloidOther hematologic neoplasm

Blast Crisis, Leukemia, Leukemia, Myeloid, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase

Data powered by HemOnc (CC BY 4.0) Colophon âš¡